Concerns about a new Alzheimer’s drug after brain swelling was discovered in 41% of patients.


Concerns about a new Alzheimer’s drug after brain swelling was discovered in 41% of patients.

The safety of the Alzheimer’s drug Aduhelm has been called into question following reports of brain swelling in 41% of patients who took the recommended dose.

FDA is looking into the new findings.

The controversial drug is suspected of being the cause of several adverse events, the most recent of which occurred in late September and is currently being investigated by the FDA. According to reports, a 75-year-old woman in Canada died after receiving infusions of the drug as part of the drug’s clinical trials.

The causes of death, according to Biogen, are still unknown.

However, according to new research published in JAMA neurology, 41% of patients who received the recommended dose of the drug experienced either swelling or bleeding in the brain.

Aduhelm, which was approved by the FDA in June, has been linked to brain swelling and bleeding.

The monoclonal antibody is given as a monthly infusion and comes with a warning on the label about these side effects, which are known scientifically as amyloid-related imaging abnormalities.

Furthermore, the FDA recommends that medical professionals monitor patients taking the drug by ordering two MRI scans during the first year of treatment.

The drug’s approval was also contentious, as a number of experts and senior FDA officials stated that it was unclear whether Aduhelm would be beneficial to patients.

When consumed more than twice daily, one drink can age the brain by ’11 years.’

Following a public records request, a biotech analyst with a medical degree obtained the case report of the Canadian deceased last week.

In a letter to clients, RBC analyst Brian Abraham mentioned the discovery.

In it, he concluded that brain swelling was the cause of death, and that it “is likely to have been caused by aducanumab.”

“The cause of death is unknown at this time,” Biogen said in response to the report.

“We know the 75-year-old clinical trial participant was admitted to the hospital after having a seizure and was diagnosed with brain swelling.”

“The patient was being prepared for discharge after a long stay in the hospital when she became ill and had to be transferred to another facility.”

“We’ve requested missing information from the critical last nine days of hospitalization, including brain imaging.”

According to a recent study published in JAMA Neurology, 362 of 1,209 patients who received an approved.

“Brinkwire News in Condensed Form.”


Comments are closed.